The effect of combination therapy with an L/N-type Ca2+ channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: An observational study conducted in Japan

Hypertension Research

Volumn 30, Issue 9, 2007, Pages 815-822

  Nagahama, Shinobu ^a   Norimatsu, Takeo ^a   Maki, Toshio ^a   Yasuda, Masaharu ^b   Tanaka, Shinsuke ^b  

^a AJINOMOTO CO INC   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Angiotensin II receptor blocker; Cilnidipine; Combination theraphy; Heart rate; Hypertension

Indexed keywords

CANDESARTAN; CILNIDIPINE; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABNORMAL SENSATION; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FLUSHING; GINGIVITIS; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; JAPAN; KIDNEY DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL STIFFNESS; NAUSEA; OBSERVATIONAL STUDY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRURITUS; RASH; RHABDOMYOLYSIS; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VOMITING;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HEART RATE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 35348839050     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.815     Document Type: Article

References (29)

1. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the Management of Hypertension for General Practitioners. Hypertens Res 2001; 24: 613-634.
2. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1-S105.
3. Oparil S, Silfani TN, Walker JF: Role of angiotensin receptor blockers; as monotherapy in reaching blood pressure goals. Am J Hypertens 2005; 18: 287-294.
4. Chobanian AV, Bakris GL, Black HR: The Seveth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment on High Blood Pressure: the JNC 7 report. JAMA 2003; 299: 2560-2572.
5. Guidelines Subcommitte: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
6. Dahlöf B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
7. Lithell H, Hansson L, Skoog I, et al, SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
8. Julius S, Kjeldsen SE, Weber M, et al, VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
9. Nissen SE, Tuzcu EM, Libby P, et al, CAMELOT Investigators: Effect of antibypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2271-2273.
10. Poole-Wilson PA, Lubsen J, Kirwan BA, et al, A Coronary disease Trial Investigating Outcome with Nifedipine Gastrointestinal Therapeutic System Investigators: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849-857.
11. Dahlöf B, Sever PS, Poulter NR, et al, ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
12. 2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurons. Br J Pharmacol 1997; 122: 37-42.
13. Minami J, Ishimitsu T, Higashi T, Numabe A, Matsuoka H: Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens Res 1998; 21: 215-219.
14. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T: The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101: 1-13.
15. ++ channel in rat dorsal root ganglionneurons. J Pharmacol Exp Ther 1997; 280: 1194.
16. Tominaga M, Ohya Y, Tsukashima A, et al: Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc Drugs Ther 1997; 11: 43-48.
17. Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K: Comparison of the effect of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res 2005; 28: 1003-1008.
18. Rose GW, Kanno Y, Ikebukuro H, et al: Cilnidipine is as effective as benazapril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24: 377-383.
19. Kojima S, Shida M, Yokoyama H: Comparison between cilnidipine and amlodipine hesitate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379-385.
20. Katamaya K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T: Comparison between valsartan and valsartan plus cilnidipeine in type 11 diabetics with normo- and microalbuminuria. Kidney Int 2006; 70: 151-156.
21. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
22. Hunter SJ, Harper R, Ennis CN, et al: Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension. J Hypertens 1998; 16: 103-109.
23. Ferrari P, Rosman J, Weidmann P: Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991; 67: 26B-35B.
24. Minami J, Ishimitsu T, Kawano Y, Nurnabe A, Matsuoka H: Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated-with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol 1998; 32: 331-336.
25. Takada M, Ura N, Higashiura K, Murakami H, Togashi N, Shimamoto K: Effects of cilnidipine on muscle fiber composition, capillary density and muscle blood flow in fructose-fed rats. Hypertens Res 2001; 24: 565-572.
26. Yagi S, Goto S, Yamamoto T, Kurihara S, Katayama S: Effect of cilnidipine on insulin sensitivity in patients with essential hypertension. Hypertens Res 2003; 26: 383-387.
27. Gillman MW, Kannel WB, Belanger A, D'Agostino RB: Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154.
28. Furberg CD, Psaty SM, Meyer JV: Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
29. Grossman E, Messerli FH: Effect of calcium antagonists on sympathetic activity. Eur Heart J 1998; 19: F27-F31.